Pathogenetic and clinical aspects of C1 inhibitor deficiency

Immunobiology

Volumn 199, Issue 2, 1998, Pages 366-376

  Cicardi, Marco ^a,b   Bergamaschini, Luigi ^a   Cugno, Massimo ^a   Beretta, Andrea ^a   Zingale, Lorenza C ^a   Colombo, Monica ^a   Agostoni, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Dipartimento di Psicologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; AUTOANTIBODY; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; THROMBIN;

ANGIONEUROTIC EDEMA; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; CATABOLISM; CLINICAL FEATURE; COMPLEMENT DEFICIENCY; DRUG MEGADOSE; FIBRINOLYSIS; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL;

EID: 0031664687     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(98)80041-7     Document Type: Article

References (34)

1. DONALDSON, V. H., and R. R. EVANS. 1963. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1 esterase. Am. J. Med. 31: 37-44.
2. BÖCK, S. C., K. SKRIVER, E. NIELSEN, H. C. THOGERSEN, B. WIMAN, V. H. DONALDSON, R. L. EDDY, J. MARRINAN, E. RADZIEJEWSKA, R. HUBER, T. B. SHOWS, and S. MAGNUSSON. 1986. Human C1 inhibitor primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25: 4292-4301.
3. DAVIS, A. E. III, K. AULAK, R. B. PARAD, et al. 1992. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics 1: 354-358.
4. VERPY, E., E. COUTURE-TOSI, E. ELDERING, M. LOPEZ-TRASCASA, P. SPATH, and T. MEO. 1995. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion and function. J. Clin. Invest. 95: 350-359.
5. ELDERING, E., E. VERPY, D. ROEM, T. MEO, and M. TOSI. 1995. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimenzation. J. Biol. Chem. 270: 2579-2587.
6. JACKSON, J., R. B. SIM, A. WHELAN, et al. 1986. An IgG autoantibody which inactivates C1-inhibitor. Nature 323: 722-724.
7. ALSENZ, J., K. BORK, and M. LOOS. 1987. Autoantibody-mediated acquired deficiency of C1 inhibitor. N. Engl. J. Med. 316: 1360-1366.
8. CUGNO, M., M. CICARDI, B. BOTTASSO, R. COPPOLA, R. PAONESSA, P. M. MANNUCCI, and A. AGOSTONI. 1997. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89: 3213-3218.
9. CICARDI, M., A. BERETTA, M. COLOMBO, D. GIOFFRE, M. CUGNO, and A. AGOSTONI. 1996. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angioedema. Clin. Exp. Immunol. 106: 475-480.
10. SCHREIBER, A. D., B. ZWEIMAN, P. ATKINS, F. GOLDWEIN, G., B. ATKINSON, and N. I. ABDOU. 1976. Acquired angioedema with lymphoproliferative disorder: Association of C1-inhibitor deficiency with cellular abnormality. Blood 48: 567-580.
11. GEHA, R. A., I. QUINTI, K. E. AUSTEN, et al. 1985. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N. Engl. J. Med. 312: 534-540.
12. MALBRAN, A., C. H. HAMMER, M. M. FRANK, and L. F. FRIES. 1988. Acquired angioedema: Observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J. Allergy Clin. Immunol. 81: 1199-1204.
13. SPÄTH, P. J., B. WUTHRICH, L. MATTER, N. LOOS, and J. ALSENZ. 1989. Acquired angioedema and anti-C1-inhibitor autoantibody. Arch. Intern. Med. 149: 1213-1214.
14. ALSENZ, J., J. D. LAMBRIS, K. BORK, and M. LOOS. 1989. Acquired C1 inhibitor (C1 INH) deficiency type II. J. Clin. Invest. 83: 1794-1799.
15. CICARDI, M., G. BISIANI, M. CUGNO, P. SPÄTH, and A. AGOSTONI. 1993. Autoimmune C1 inhibitor deficiency: report of eight patients. Am. J. Med. 95: 169-175.
16. MANDLE, R., C. BARON, E. ROUX, R. SUNDEL, J. GELFAND, K. AULAK, A. E. III DAVIS, F. S. ROSEN, and D. H. BING. 1994. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J. Immunol. 152: 4680-4685.
17. DONALDSON, V. H., C. J. WAGNER, and A. E. III DAVIS. 1996. An autoantibody to C1 inhibitor recognizes the reactive center of the inhibitor. J. Lab. Clin. Med. 127: 229-232.
18. HE, S., S. TSANG, J. NORTH, N. COLAN, R. J. SIM, and K. WHALEY. 1996. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J. Immunol. 156: 288-294.
19. FRIGUET, B., A. F. CHAFFOTTE, L. DJAVADI-OHANIANCE, and M. E. GOLDBERG. 1985. Measurement of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods. 77: 305-319.
20. FIELDS, T., B. GHEBREHIWET, and A. P. KAPLAN. 1983. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of «spontaneous» formation of bradykinin. J. Allergy Clin. Immunol. 72: 54.
21. SCHAPIRA, M., L. D. SILVER, C. F. SCOTT, et al. 1983. Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308: 1050-1053.
22. STRANG, C. J., S. CHOLIN, A. E. III DAVIS, E. E. SCHNEEBERGER, V. H. DONALDSON, and F. S. ROSEN. 1988. Angioedema induced by a peptide derived from complement component C2. J. Exp. Med. 168: 1685-1688.
23. DAVIS, A. E. III. 1988. C1 inhibitor and hereditary angioneurotic edema. Ann. Rev. Immunol. 6: 595-628.
24. DE LA CADENA, R. A., Y. T. WACHTFOGEL, and R. W. COLMAN. 1994. Contact activation pathway: inflammation and coagulation, in COLMAN, R. W., HIRSH, J., MARDER, W. J., SALZMAN, E. W. (eds.): Hemostasis and thrombosis: principles and clinical practice. Philadelphia, PA, J. B. Lippincott Company, 219-240.
25. KLENIEWSKY, J., D. T. BLANKENSHIP, A. D. CARDIN, and V. DONALDSON. 1992. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J. Lab. Clin. Med. 120: 129-139.
26. CUGNO, M., C. E. HACK, J. P. DE BOER, A. J. M. EERENBERG, A. AGOSTONI, and M. CICARDI. 1993. Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med. 121:38-43.
27. CUGNO, M., M. CICARDI, and A. AGOSTONI. 1994. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of Tranexamic acid. J. Allergy Clin. Immunol. 93: 870-876.
28. RAPAPORT, S. I., and L. V. M. RAO. 1995. The tissue factor pathway: how it has become «prima ballerina». Thromb. Haemost. 74: 7.
29. DE MICHELE, M. A. A., D. G. MOON, J. W. II FENTON, and F. N. MINNEAR. 1990. Thrombin's enzymatic activity increases permeability of endothelial cell monolayers. J. Appl. Physiol. 69:1599.
30. AGOSTONI, A., and M. CICARDI. 1992. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 71: 206-215.
31. CICARDI, M., P. M. MANNUCCI, R. CASTELLI, M. G. RUMI, and A. AGOSTONI. 1995. Reduction in transmission of hepatitis C after the introduction of heat treatment step in the production of C1-inhibitor concentrate. Transfusion 35: 209-212.
32. DE FILIPPI, F., R. CASTELLI, M. CICARDI, et al. 1998. Transmission of hepatitis G virus in patients with angioedema treated with steam-inactivated plasma concentrates of C1-inhibitor. Transfusion 38: 307-311.
33. GELFAND, J. A., R. J. SHERINS, D. W. ALLING, and M. M. FRANK. 1976. Treatment of hereditary angioedema with Danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 293: 1444-1448.
34. CICARDI, M., R. CASTELLI, L. C. ZINGALE, and A. AGOSTONI. 1997. Side effect of long-term prophylaxis with attenuated androgens in hereditary angioedema: Comparison of treated and untreated patients. J. Allergy Clin. Immunol. 99: 194-196.